Table 1.

The antiproliferative activities evaluated in five kinds of human cancer cell lines ^a.

Compds	IC50, Mean ± SE (μΜ) b
	A549	Caski	HepG2	C42B	MCF-7
5a	0.812 ± 0.022	1.929 ± 0.035	0.963 ± 0.032	1.377 ± 0.021	1.553 ± 0.014
5b	0.362 ± 0.017	0.729 ± 0.033	0.461 ± 0.017	0.577 ± 0.021	0.350 ± 0.011
11a	0.631 ± 0.018	0.832 ± 0.011	0.998 ± 0.034	0.911 ± 0.034	0.816 ± 0.045
11b	0.208 ± 0.009	0.516 ± 0.012	0.454 ± 0.021	0.455 ± 0.015	0.651 ± 0.024
14a	0.072 ± 0.004	0.086 ± 0.009	0.142 ± 0.014	0.089 ± 0.021	0.082 ± 0.011
14b	0.022 ± 0.002	0.037 ± 0.003	0.074 ± 0.013	0.051 ± 0.005	0.027 ± 0.006
19a	1.321 ± 0.016	2.311 ± 0.019	3.098 ± 0.021	2.411 ± 0.042	1.775 ± 0.004
19b	0.642 ± 0.081	1.098 ± 0.032	0.898 ± 0.009	1.076 ± 0.034	1.021 ± 0.015
21a	0.105 ± 0.011	0.211 ± 0.012	0.441 ± 0.071	0.209 ± 0.020	0.121 ± 0.021
21b	0.082 ± 0.010	0.106 ± 0.012	0.097 ± 0.031	0.107 ± 0.006	0.099 ± 0.031
Compd. A	0.226 ± 0.035	0.892 ± 0.024	0.758 ± 0.017	0.526 ± 0.007	0.456 ± 0.021
Millepachine	2.566 ± 0.131	6.712 ± 0.233	3.881 ± 0.244	3.176 ± 0.384	4.528 ± 0.338

^a Cell lines were treated with different concentrations of the compounds for 48 h. Cell viability was measured by a CCK-8 assay, as described in the Materials and Methods section. ^b IC₅₀ values are indicated as the mean ± SE (standard error) of at least three independent experiments.